Accumulating data on rivaroxaban for venous thromboembolism in clinical practice

Thromb Haemost 2017; 117(10): 1840
DOI: 10.1160/TH17-08-0573

Invited Editorial Focus

Schattauer GmbH

Sam Schulman

¹Thrombosis and Atherosclerosis Research Institute and McMaster University, Hamilton, Ontario, Canada

References
1 Schulman S, Singer D, Ageno W. et al. NOACs for treatment of venous thromboembolism in clinical practice. Thromb Haemost 2017; 117: 1317-1325.
2 Bauersachs R, Berkowitz SD, Brenner B. et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
3 Buller HR, Prins MH, Lensing AW. et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297.
4 Coleman CI, Bunz TJ, Turpie AGG. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism. Thromb Haemost 2017; 117: 1841-1847.
5 Sindet-Pedersen C, Pallisgaard JL, Staerk L. et al. Comparative safety and effectiveness of rivaroxaban versus vitamin K antagonists in patients with venous thromboembolism – A Danish nationwide registry-based study. Thromb Haemost 2017; 117: 1182-1191.